Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Offers Workshop On Non-Inferiority Studies Of Antibacterial Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

How to set the margins in non-inferiority studies of new antibacterial drugs is the hard question the workshop will tackle.
Advertisement

Related Content

Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
FDA Shows When And How To Use, Or Not To Use, Non-Inferiority Trials
CAP Drugs Must Meet Stricter Noninferiority Criteria Under Draft FDA Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS070827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel